title: Preoperative plasma aldosterone and the risk of atrial fibrillation after coronary artery bypass surgery: a prospective cohort study.
abstract: Postoperative atrial fibrillation (POAF) is associated with poor outcomes after coronary artery bypass graft (CABG) surgery. We aimed to assess the additional value of preoperative plasma aldosterone levels, a biomarker promoting proarrhythmic and profibrotic pathways, for predicting POAF after CABG.
  
  
  
  We conducted a prospective cohort study involving consecutive patients with left ventricular ejection fraction (LVEF) more than 50% requiring elective CABG in our university hospital. Plasma aldosterone levels, two-dimensional echocardiography including left atrial strain analysis and galectin-3 (Gal-3) examination were assessed before cardiac surgery. The primary endpoint was the occurrence of POAF within 30 days after surgery.
  
  
  
  POAF occurred in 34 (24.8%) out of the 137 included patients. Compared with controls, patients experiencing POAF were significantly older (73 years old ± 8 vs 65 ± 11, P < 0.001) and had higher preoperative plasma aldosterone levels [183 pmol/l (interquartile range 138-300) vs 143 pmol/l (interquartile range 96.5-216.5), P < 0.01]. Age [odds ratio (OR), 1.088; 95% confidence interval (CI) (1.038-1.140); P = 0.0004] and plasma aldosterone levels [OR, 1.007; 95% CI (1.003-1.012); P = 0.0013] were independently associated with POAF in multivariate analysis and could therefore be combined to predict the occurrence of POAF ['Aldoscore', OR, 2.7; 95% CI (1.7-4.3); P < 0.0001]. Reverse transcriptase PCR analysis performed on right atrial appendage and plasma examination revealed that Gal-3 was activated in POAF patients.
  
  
  
  We developed the preoperative 'Aldoscore' for POAF risk stratification among patients with preserved LVEF requiring elective CABG. This new tool may be helpful to identify good responders to interventions targeting the proarrhythmic and profibrotic pathways of aldosterone.
authors: aDepartment of Pharmacology, CHU de Caen bNormandie Univ, UNICAEN, CHU Caen, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique cDepartment of Cardiology, CHU de Caen dDepartment of Biochemistry ePôle Réanimations Anesthésie SAMU/SMUR fDepartment of Cardiac Surgery, CHU de Caen, Caen gDepartment of Pharmacology, GH Pitié-Salpétrière, Paris, France hDepartment of Cardiovascular Sciences, Sapienza University, Rome, Italy iDepartment of Nuclear Medicine jDepartment of Biostatistics and Clinical Research, CHU de Caen, Caen, France.
authors: Joachim
authors: J
authors: Alexandre
authors: Eric
authors: E
authors: Saloux
authors: Mathieu
authors: M
authors: Chequel
authors: Stéphane
authors: S
authors: Allouche
authors: Pierre
authors: P
authors: Ollitrault
authors: Anne-Flore
authors: AF
authors: Plane
authors: Damien
authors: D
authors: Legallois
authors: Marc-Olivier
authors: MO
authors: Fischer
authors: Vladimir
authors: V
authors: Saplacan
authors: Dimitrios
authors: D
authors: Buklas
authors: Fabien
authors: F
authors: Labombarda
authors: Katrien
authors: K
authors: Blanchart
authors: Joe-Elie
authors: JE
authors: Salem
authors: Marie
authors: M
authors: Nowoczyn
authors: Paolo-Emilio
authors: PE
authors: Puddu
authors: Alain
authors: A
authors: Manrique
authors: Jean-Jacques
authors: JJ
authors: Parienti
authors: Paul
authors: P
authors: Milliez
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000450:Aldosterone / Q000097:blood*; D001281:Atrial Fibrillation / Q000209:etiology*; D015415:Biomarkers / Q000097:blood; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004452:Echocardiography; D005260:Female; D006325:Heart Atria / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology*; D011237:Predictive Value of Tests; D057234:Preoperative Period; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D000450:Aldosterone